Singapore markets close in 3 hours 35 minutes

CSL Limited (CSL.AX)

ASX - ASX Delayed Price. Currency in AUD
Add to watchlist
296.38+3.14 (+1.07%)
As of 03:05PM AEST. Market open.
Full screen
Previous close293.24
Bid296.38 x 13700
Ask296.40 x 21700
Day's range293.00 - 298.38
52-week range240.10 - 319.78
Avg. volume845,480
Market cap142.768B
Beta (5Y monthly)0.16
PE ratio (TTM)41.34
EPS (TTM)7.17
Earnings date17 Aug 2022
Forward dividend & yield2.85 (0.97%)
Ex-dividend date07 Mar 2022
1y target est314.57
  • Business Wire

    Finalization of Vifor Pharma acquisition

    MELBOURNE, Australia & ST. GALLEN, Switzerland, August 02, 2022--Regulatory News: This press release features multimedia. View the full release here:

  • Reuters

    EU regulators investigate Vifor Pharma over anti-competitive behaviour

    EU antitrust regulators are investigating whether Vifor Pharma, which is being acquired by CSL Ltd, disparaged its rival Pharmacosmos in order to hinder competition with its blockbuster iron deficiency medicine Ferinject. The European Commission, which opened the probe on Monday, said it was concerned that Swiss drugmaker Vifor Pharma pursued a misleading marketing campaign, primarily targeting healthcare professionals.

  • CNW Group

    Seqirus Receives Health Canada Approval for Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People as Young as Six Months

    Seqirus, a global leader in influenza prevention, announced today that it has received Health Canada approval of FLUCELVAX® QUAD (Influenza Vaccine), its cell-based quadrivalent influenza vaccine for an expanded age indication for children as young as six months old.1 With this approval, FLUCELVAX® QUAD, the first cell-based influenza vaccine available in Canada, is now indicated for everyone eligible to receive an influenza vaccine in Canada.2